Experiment 1
After analyzing the results of the human clinical trial, we can come to the conclusion that the higher dosage of the LPS drug is directly correlated to the amount of Inflammotin produced in the body. We can come to this conclusion because after running the Anova tests and the Post-hoc tests for the human clinical trial, the numbers proved to be significant.
Experiment 2
Our analysis for the rat trials is inconclusive. We could not come to a conclusion for the rat trials because after preforming the t-test on the data that was gathered the p-value told us that the data gathered had no significance and could not be either right or wrong, therefore we came to the conclusion of inconclusive.
Summary/Discussion
In this experiment we can conclude that there is a statistical difference between groups in the human clinical trial, however in the rat test the same cannot be said. This is perfectly illustrated by the p-value from the ANOVA test and post-hoc test in the humans and the t-test in the rats. Nothing can be concluded between the two groups because the rat test had serious problems in experiment design. Between the lack of test subjects, lack of variety between dosages, and the inconsistencies in the data, the rat test could not provide any conclusive data. In our analysis in the human clinical trial we compared the age to the amount of inflammotin created by the same amount of dosage. While there was a general trend, nothing can be concluded due to a Pearson's r value of less than .95 for both the 10mg LPS and the 15mg LPS.
BME 100 Fall 2014
